ClinicalTrials.gg
RecruitingNCT07161414ARTEMIDE-subQUpdated Oct 5, 2026

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

A Phase 1 interventional study of IV Rilvegostomig and Recombinant Human Hyaluronidase (rHu) in Advanced Solid Tumors, sponsored by AstraZeneca. Recruiting at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 5, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

Read the detailed description

This is a Phase I, open-label, multicenter, multi-part, dose finding and dose confirmation study to evaluate the PK and safety of SC rilvegostomig.

The study includes 2 parts: Part 1 (Dose Finding) and Part 2 (Dose Confirmation).

Part 1 will determine a SC rilvegostomig dose co-administered with rHu that yields drug exposure comparable with IV rilvegostomig. It will include 2 planned dose levels (DL1 in Cohort A and DL2 in Cohort B). Additional dose levels may be added, if needed.

Part 2 will be initiated once a dose has been identified based on Part 1. This part will evaluate the bioavailability, safety, and tolerability of SC rilvegostomig + rHu.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Recombinant Human Hyaluronidase
  • Immunooncology monotherapy
  • T cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Domain (TIGIT)
  • Programmed Cell Death Protein 1 (PD-1)
  • Bispecific immunotherapy
  • Checkpoint inhibitor
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented advanced ( and/or unresectable) solid tumor.
  • Participants must have received prior anticancer treatment for the disease under study: this may include chemotherapy, immunotherapy, or targeted therapy as considered standard of care, where clinically appropriate.
  • IO monotherapy considered clinically appropriate and reasonably likely to permit study participation through at least the PK-evaluable period, in the investigator's judgment.
  • (ECOG) performance status of 0 or 1 at enrollment with no deterioration.
  • Minimum of ≥ 12 weeks at enrollment.
  • Adequate organ and marrow function.
  • Body weight ≥ 30 kg.

Exclusion criteria

Exclusion Criteria:

  • Any severe or uncontrolled systemic diseases, which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
  • History of organ transplant or stem cell transplant.
  • History of another primary that was active within past 2 years.
  • Persistent toxicities caused by previous anticancer treatment(s) excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
  • Unstable, symptomatic or spinal cord compression.
  • History of .
  • Active primary immunodeficiency/active infectious disease including tuberculosis (TB), (HIV) infection or or C infection or any other active or uncontrolled infection requiring systemic treatment.
  • or uncontrolled cardiovascular disease, including clinically significant arrhythmias, symptomatic heart failure, cardiomyopathy or myocarditis, recent myocardial infarction or unstable angina, or uncontrolled hypertension.
  • Active or ongoing interstitial lung disease (ILD)/ pneumonitis, serious chronic gastrointestinal conditions associated with diarrhea; primary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
  • Active or prior documented or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, , or drugs.
  • Known allergy or to rilvegostomig, hyaluronidase, or any of the products.
  • Participants experienced a toxicity to prior immunotherapy that led to permanent discontinuation of prior immunotherapy.
  • Prior anticancer treatment, including immunotherapy, up to 28 days prior to the first dose of study treatment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Part 1 (dose finding): Cohort A - SC Rilvegostomig Dose Level 1 (DL1) and rHu

    Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with recombinant human hyaluronidase (rHu) and SC rilvegostomig (DL1) at predefined intervals.

    Drug: IV Rilvegostomig · Drug: Recombinant Human Hyaluronidase (rHu) · Drug: SC Rilvegostomig

  • Experimental
    Part 1 (dose finding): Cohort B - SC Rilvegostomig DL2 and rHu

    Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with rHu and SC rilvegostomig (DL2) at predefined intervals.

    Drug: IV Rilvegostomig · Drug: Recombinant Human Hyaluronidase (rHu) · Drug: SC Rilvegostomig

  • Experimental
    Part 2 (dose confirmation): SC Rilvegostomig and rHu

    Participants will receive SC rilvegostomig and rHu.

    Drug: SC rilvegostomig + rHu

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-time Curve During One Dosing Interval (AUCtau)

    Bioavailability based on AUCtau at first SC dose will be determined.

    Time frame: From Day 1 up to end of Cycle 2 in Part 1 and end of Cycle 1 in Part 2 (each cycle will be of 3 weeks)

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    To assess safety and tolerability of SC rilvegostomig. Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE version 5.0), clinical laboratory assessments, vital signs, physical examinations, and ECOG performance status.

    Time frame: From Day 1 up to 90 days post last dose (Up to approximately 23 months)

  2. Observed Lowest Concentration before the Next Dose is Administered (Ctrough)

    To assess drug exposure (Ctrough) of SC rilvegostomig comparable to that of IV rilvegostomig.

    Time frame: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).

  3. Average drug concentration over a dosing interval (Cavg)

    To assess drug exposure (Cavg) of SC rilvegostomig comparable to that of IV rilvegostomig.

    Time frame: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).

  4. AUCtau

    To assess drug exposure of SC rilvegostomig comparable to that of IV rilvegostomig.

    Time frame: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).

  5. Serum rilvegostomig concentration

    To assess drug exposure (serum concentration) of SC rilvegostomig comparable to that of IV rilvegostomig.

    Time frame: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).

07

Study locations

8 of 11 sites recruiting
  • Research Site
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Barcelona, 08035, Spain
    Not yet recruiting
  • Research Site
    Barcelona, 08036, Spain
    Recruiting
  • Research Site
    Madrid, 28027, Spain
    Recruiting
  • Research Site
    Madrid, 28040, Spain
    Recruiting
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Sutton, SM2 5PT, United Kingdom
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 8, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Jul 19, 2027
CompletionEst.
Jul 24, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 5 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants must have received prior anticancer treatment for the disease under study: this may include chemotherapy, immunotherapy, or targeted therapy as considered standard of care, where clinically appropriate.
  • ChangedBefore IO monotherapy deemed appropriate by the investigator.Now IO monotherapy considered clinically appropriate and reasonably likely to permit study participation through at least the PK-evaluable period, in the investigator's judgment.
Exclusion criteria
  • EditedHistory of organ transplant or allogeneic stem cell transplant.
  • EditedActive primary immunodeficiency/active infectious disease including tuberculosis (TB), human immunodeficiency virus (HIV) infection or hepatitis A, B or C infection or any other active or uncontrolled infection requiring systemic treatment.
  • ChangedBefore History of clinically significant arrhythmia, cardiomyopathy of any etiology; symptomatic congestive heart failure, history of myocardial infarction within the past 6 months.Now Clinically significant or uncontrolled cardiovascular disease, including clinically significant arrhythmias, symptomatic heart failure, cardiomyopathy or myocarditis, recent myocardial infarction or unstable angina, or uncontrolled hypertension.
  • EditedUncontrolled intercurrent illness including but not limited to ongoingActive or active known infection;ongoing interstitial lung disease (ILD)/ pneumonitis, serious chronic gastrointestinal conditions associated with diarrhea; activeprimary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
  • EditedActive or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with steroidsthe use of disease-modifying agents, corticosteroids, or other immunosuppressive treatmentdrugs.
Oct 5, 2026
Secondary outcomes
5 time frame changed
What changed in the outcomes
  • Time frameNumber of participants with adverse events (AEs)From Day 1 up to 90 days post last dose (Up to approximately 29 months) → From Day 1 up to 90 days post last dose (Up to approximately 23 months)
  • Time frameObserved Lowest Concentration before the Next Dose is Administered (Ctrough)From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
  • Time frameAverage drug concentration over a dosing interval (Cavg)From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
  • Time frameAUCtauFrom first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
  • Time frameSerum rilvegostomig concentrationFrom first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Eligibility 2 inclusion criteria edited; 5 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants must have received prior anticancer treatment for the disease under study: this may include chemotherapy, immunotherapy, or targeted therapy as considered standard of care, where clinically appropriate.
    • ChangedBefore IO monotherapy deemed appropriate by the investigator.Now IO monotherapy considered clinically appropriate and reasonably likely to permit study participation through at least the PK-evaluable period, in the investigator's judgment.
    Exclusion criteria
    • EditedHistory of organ transplant or allogeneic stem cell transplant.
    • EditedActive primary immunodeficiency/active infectious disease including tuberculosis (TB), human immunodeficiency virus (HIV) infection or hepatitis A, B or C infection or any other active or uncontrolled infection requiring systemic treatment.
    • ChangedBefore History of clinically significant arrhythmia, cardiomyopathy of any etiology; symptomatic congestive heart failure, history of myocardial infarction within the past 6 months.Now Clinically significant or uncontrolled cardiovascular disease, including clinically significant arrhythmias, symptomatic heart failure, cardiomyopathy or myocarditis, recent myocardial infarction or unstable angina, or uncontrolled hypertension.
    • EditedUncontrolled intercurrent illness including but not limited to ongoingActive or active known infection;ongoing interstitial lung disease (ILD)/ pneumonitis, serious chronic gastrointestinal conditions associated with diarrhea; activeprimary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
    • EditedActive or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with steroidsthe use of disease-modifying agents, corticosteroids, or other immunosuppressive treatmentdrugs.
    Secondary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameNumber of participants with adverse events (AEs)From Day 1 up to 90 days post last dose (Up to approximately 29 months) → From Day 1 up to 90 days post last dose (Up to approximately 23 months)
    • Time frameObserved Lowest Concentration before the Next Dose is Administered (Ctrough)From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
    • Time frameAverage drug concentration over a dosing interval (Cavg)From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
    • Time frameAUCtauFrom first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
    • Time frameSerum rilvegostomig concentrationFrom first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 29 months). → From first dose of study intervention (Day 1), at predefined intervals throughout the administration of rilvegostomig (approximately 23 months).
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07161414
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Nov 25, 2025
Primary completion
Jul 19, 2027 (estimated)
Completion
Jul 24, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilvegostomig

Start the discussion